In this view, it has been demonstrated that lower doses of anti-VEGF receptor 2 (VEGFR2) antibodies, but not high anti-angiogenic doses, result in a more homogeneous distribution of functional tumor vessels. This evidence concerns the gene KDR and neoplasm.